Excessive intra-pancreatic fat deposition (IPFD) is a key driver of common diseases of the pancreas. It is also a well-established risk factor for a wide range of cardio-metabolic conditions, including type 2 diabetes mellitus, as well as microvascular and macrovascular complications. Lipid metabolism has been implicated in the pathogenesis of fatty pancreas and may serve as a basis for future therapeutic interventions. However, despite its clinical significance, the related lipid biomarkers in the context of IPFD are poorly understood. This talk will focus on the recently uncovered relationship between IPFD and a comprehensive panel of lipid biomarkers – including triglyceride-rich lipoproteins (TRL), high-density lipoprotein (HDL) subfractions, low-density lipoprotein subfractions, various apolipoproteins, as well as lipidomics – in individuals from the general population.